Chimeric IL‐6/4R‐LL37 Engineered Macrophages Achieve Synchronized Inflammation Control and Antimicrobial Defence in Sepsis
Advanced Science · 2026
DOI: 10.1002/advs.77016 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Science, 2026. Verfasst von Tianyang Jie und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Bone and Joint Surgery, Department of Orthopedics, Renji Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China. Hauptthemen laut MEDLINE: Sepsis, Macrophages, Interleukin-6, Inflammation. Die Arbeit nennt 53 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, National Key Research and Development Program of China, Shanghai Shuguang Plan Project.
Themen: Sepsis
Abstract (Originalsprache)
Treatment of septic patients is confronted with complex immune dysregulation: excessive pro‐inflammatory responses trigger cytokine storm leading to organ damage and high mortality, while concurrent and persistent immune dysfunction manifesting as T cell exhaustion, monocyte and macrophage functional suppression, and impaired antigen presentation significantly increases the risk of secondary infections. Current clinical therapeutic strategies can effectively control infection and cytokine storm, but fail to resolve persistent T cell exhaustion, which is a critical determinant of poor long‐term survival in sepsis patients. This study reported a multifunctional engineered macrophage therapeutic strategy based on in situ LNP delivery of IL‐6/4 fusion protein and LL37 antimicrobial peptide mRNA. The IL‐6/4 fusion blocks IL‐6 mediated pro‐inflammatory signaling and activates IL‐4 mediated anti‐inflammatory pathways, reducing inflammatory injury and promoting tissue repair. LL37 antimicrobial peptide disrupts bacterial membranes to reduce bacterial burden while modulating immune responses. In sepsis mouse models, engineered macrophages significantly improved survival rates, reduced histopathological damage and organ bacterial burden, and effectively restored T cell and macrophage functions, achieving infection control, inflammation modulation, and immune reconstitution. These findings demonstrate the substantial clinical translational potential of this engineered macrophage approach for precision sepsis treatment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Bone and Joint Surgery, Department of Orthopedics, Renji Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China.
- Department of Interventional Oncology, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
ORCID-Profile: Hao Zhang, Penglong Zheng, Sijia Zhou, Xinhua Qu, Bing Yue
Förderung
- National Natural Science Foundation of China
- National Key Research and Development Program of China
- Shanghai Shuguang Plan Project
- Shanghai Municipal Health Commission & Shanghai "Rising Stars of Medical Talent"
- Youth Development Program-Outstanding Youth Medical Talents
Zitieren
APA
Jie, T., Zhang, Z., Zhang, H., Bian, L., Zheng, P., Zhou, S., Wang, M., Qu, M., Wang, Y., Qu, X., & Yue, B. (2026). Chimeric IL‐6/4R‐LL37 Engineered Macrophages Achieve Synchronized Inflammation Control and Antimicrobial Defence in Sepsis. Advanced Science. https://doi.org/10.1002/advs.77016
Vancouver
Jie T, Zhang Z, Zhang H, Bian L, Zheng P, Zhou S, et al. Chimeric IL‐6/4R‐LL37 Engineered Macrophages Achieve Synchronized Inflammation Control and Antimicrobial Defence in Sepsis. Advanced Science. 2026. doi:10.1002/advs.77016
BibTeX
@article{Jie2026,
author = {Jie, Tianyang and Zhang, Zheyu and Zhang, Hao and Bian, Linke and Zheng, Penglong and Zhou, Sijia and Wang, Minqi and Qu, Mingyu and Wang, Yufei and Qu, Xinhua and Yue, Bing},
title = {Chimeric IL‐6/4R‐LL37 Engineered Macrophages Achieve Synchronized Inflammation Control and Antimicrobial Defence in Sepsis},
journal = {Advanced Science},
year = {2026},
doi = {10.1002/advs.77016}
}
EUVIMED